S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

Bibliographic Details
Main Authors:	O. Al-Sawaf, C. Zhang, S. Robrecht, A. Kotak, N. Chang, A.-M. Fink, E. Tausch, C. Schneider, M. Ritgen, K.-A. Kreuzer, B. Chyla, B. Eichhorst, Y. Jiang, S. Stilgenbauer, M. Hallek, K. Fischer
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000843484.72409.00

Similar Items

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
by: Othman Al-Sawaf, et al.
Published: (2023-08-01)

S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB
by: O. Al-Sawaf, et al.
Published: (2022-06-01)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2023-04-01)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2023-10-01)

P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS
by: P. Cramer, et al.
Published: (2022-06-01)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
by: Natali Pflug, et al.
Published: (2021-12-01)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
by: Deyan Yosifov, et al.
Published: (2023-08-01)

Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
by: Paul J. Hengeveld, et al.
Published: (2025-01-01)

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2019-05-01)

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
by: Nadine Kutsch, et al.
Published: (2022-04-01)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
by: Nadine Kutsch, et al.
Published: (2022-06-01)

Use of obinutuzumab for refractory autoimmune thrombocytopenia secondary to CLL
by: Rohitashva Agrawal, et al.
Published: (2020-07-01)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
by: Stephan Stilgenbauer, et al.
Published: (2020-10-01)

P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.
by: Steven Le Gouill, et al.
Published: (2023-08-01)

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
by: Al-Sawaf O, et al.
Published: (2017-01-01)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
by: Petra Langerbeins, et al.
Published: (2023-08-01)

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial
by: Paula Cramer, et al.
Published: (2020-02-01)

The role of trephine bone marrow biopsies in the era of measurable residual disease—Results from the CLL10 trial of the German CLL Study Group (GCLLSG)
by: Nadine Kutsch, et al.
Published: (2024-07-01)

PB1938: REAL WORLD EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN TREATMENT NAIVE CLL PATIENTS – DATA FROM THE OBSERVATIONAL STUDY VERVE
by: Ingo Schwaner, et al.
Published: (2023-08-01)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
by: Florian Simon, et al.
Published: (2023-08-01)

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
by: Annamaria Mascolo, et al.
Published: (2023-08-01)

S146: VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION: 6-YEAR FOLLOW-UP AND GENOMIC ANALYSES IN A PIVOTAL PHASE 2 TRIAL
by: S. Stilgenbauer, et al.
Published: (2022-06-01)

Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia
by: Eugen Tausch, et al.
Published: (2019-09-01)

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
by: Moritz Fürstenau, et al.
Published: (2019-10-01)

P681: EUROFLOW STANDARDIZATION TECHNIQUE AND NORMALIZATION PROCEDURES IN LONGITUDINAL FLOW CYTOMETRIC EXPRESSION ANALYSIS OF CD20 IN CLL PATIENTS RECEIVING ANTI-CD20 DIRECTED THERAPY
by: P. J. Walter, et al.
Published: (2022-06-01)

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)
by: Sonia Jaramillo, et al.
Published: (2019-12-01)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
by: James D’Rozario, et al.
Published: (2019-05-01)

Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
by: Nishika Karbhari, et al.
Published: (2022-03-01)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
by: Andrea Visentin, et al.
Published: (2022-11-01)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
by: Andrew Grigg, et al.
Published: (2017-04-01)

Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia
by: Courtney Samuels, et al.
Published: (2022-05-01)

Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study
by: Véronique Leblond, et al.
Published: (2018-11-01)

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia
by: P. J. Hengeveld, et al.
Published: (2023-07-01)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
by: A. R. Mato, et al.
Published: (2022-06-01)

S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL
by: P. Hillmen, et al.
Published: (2022-06-01)

MATCHING-ADJUSTED INDIRECT COMPARISON OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
by: O Al-Sawaf, et al.
Published: (2023-10-01)

Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab
by: Jacopo Olivieri, et al.
Published: (2022-06-01)

P1713: VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS
by: D. Kanevsky, et al.
Published: (2022-06-01)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
by: Pin Lu, et al.
Published: (2021-02-01)

P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL
by: Arnon Kater, et al.
Published: (2023-08-01)